@article {8103,
	title = {Randomized trials of adjuvant and neoadjuvant chemotherapy in bladder cancer},
	journal = {Seminars in Urologic Oncology},
	volume = {19},
	year = {2001},
	note = {Cited By :4Export Date: 21 February 2017},
	month = {2001},
	pages = {59 - 65},
	abstract = {Data of randomized studies of adjuvant and neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer were reviewed. Four adjuvant studies have been published. The interpretation of their data is compromised primarily because of small patient numbers. Thus, a possible survival advantage cannot be documented, and significantly larger, prospective studies are needed. However, there is some evidence of improved disease-free survival for patients with non-organ-confined tumors treated with cisplatin-based combination chemotherapy. More data are available for neoadjuvant chemotherapy. The already published randomized studies, including a large trial of who was designed to detect a 10\% survival benefit, do not indicate a significant advantage for neoadjuvant chemotherapy. Radical cystectomy remains the standard treatment to which other therapeutic modalities must be compared. Copyright {\textcopyright} 2001 by W.B. Saunders Company.},
	keywords = {Adjuvant, Bladder cancer, Neoadjuvant chemotherapy},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0035108854\&partnerID=40\&md5=951dea17f62c86f585b7398a9892a535},
	author = {Dimopoulos, M.A. and Galani, E.}
}
